The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

The invention provides safe and efficacious treatments for the improvement of sexual function such as Genitopelvic Pain/Penetration Disorders; vulvovaginal atrophy, vestibulodynia, dyspareunia, Sexual Interest/Arousal Disorder, low female libido and Female Orgasmic Disorder.

Disclosed is a fusion protein for α-Melanocyte stimulating hormone, the fusion protein containing a protein transduction domain (PTD), a human serum albumin (HSA) and an α-Melanocyte stimulating hormone (α-MSH). Also disclosed are a method for preparing the fusion protein and a use thereof for inhibiting or treating central nervous system inflammations.

Disclosed is a fusion protein for α-Melanocyte stimulating hormone, the fusion protein containing a protein transduction domain (PTD), a human serum albumin (HSA) and an α-Melanocyte stimulating hormone (α-MSH). Also disclosed are a method for preparing the fusion protein and a use thereof for inhibiting or treating central nervous system inflammations.

Formulations, compositions and methods for delivery of melanocortin receptor-specific peptides, particularly cyclic peptides selective and specific for the melanocortin-1 receptor, to the lumen of the gastrointestinal tract for treatment of melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes of the gastrointestinal tract.

The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions.

The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions.

The present invention relates to novel peptide compounds which are effective as melanocortin 4 receptor agonists, to the use of the compounds in medicine, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds for the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of overweight and obesity as well as a variety of diseases or conditions associated with obesity.

The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.

The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.